 Histogen Inc. HSTO, a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at BIO Digital 2020, being held virtually June 8-12, 2020. In addition to completion of its merger with Conatus Pharmaceuticals in May 2020, enrollment is currently underway in Histogens Phase 1b2a clinical trial of its lead product candidate, HST 001, for male pattern hair loss. Histogen also anticipates clinical advancement of HST 002, a novel dermal filler product, and HST 003, a product targeting joint cartilage regeneration, this year. 